Notably, the 2022 World Health Organization (WHO) [2] classification has eliminated the blast percentage prerequisite for the diagnosis of NPM1-mutated AML though emphasizes the necessity of an integrated diagnosis based on clinicopathologic correlation. This evidence concerns the gene NPM1 and acute myeloid leukemia.